Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 December 2021 | Story Leonie Bolleurs | Photo Supplied
Ofhani Mavhungu was recently awarded the Professor Rob Gous Scholarship by the Animal Feed Manufacturers Association (AFMA) of South Africa.

From a very early age, Ofhani Mavhungu knew he wanted to be involved in agriculture one day. Fast forward a few decades and you find Ofhani enrolled for the MScAgric Animal Science degree at the University of the Free State (UFS).

As a goal-orientated person who is open to new ventures, he reckons this degree will broaden his knowledge and understanding of the industry. “I believe Animal Science is an interdisciplinary field of study that enables students like me to pursue various career opportunities, ranging from primary animal production to secondary product processing, retail, and quality assurance. This motivates me to be part of the team that will ensure food security for the future generation,” says Ofhani.

Opening doors to a career in Animal Science

The Professor Rob Gous Scholarship for 2020/2021 that was jointly awarded to him and Victor Makofane of the University of Limpopo by the Animal Feed Manufacturers Association (AFMA) of South Africa, is for Ofhani a step closer to realising his dreams. 

“Diligence and hard work have always been the driving force throughout my studies, and I am delighted that my hard work was rewarded. This award further reflects on the Department of Animal Science’s dedication and commitment to build and mentor strong candidates who are recognised by the industry,” he says.

With increasing animal feed costs, the search for more cost-effective feed utilisation techniques – without compromising the nutritive value or feed quality – becomes critically important for intensive broiler producers. 

Ofhani’s study, which aims to evaluate the effect of increasing levels of a nutritional fat emulsifier with a high HLB on the (i) diet digestibility and (ii) production performance of broilers, will provide some insight into the possible energy-saving effect of dietary emulsifiers with a high HBL in broiler diets with moderate lipid inclusion levels. 

“A digestibility study will give more information on the emulsifier effect at metabolic level, and a production study will provide information on growth characteristics and carcass composition.”

An opportunity to compete with other candidates in the industry

“Few studies have been conducted on lipid emulsifiers under South African conditions, which necessitates the need for further research in this field,” he says. 

Ofhani, whose motto in life is to stay humble and accept positive criticism – as it is meant to enlighten you – wants to pursue a career in the animal feed industry. “My qualification will give me an opportunity to compete with other candidates of our generation in the industry, as well as on a research/academic level. By completing my MScAgric, I will broaden my own skill set so that I can continue with industry-related research in the future and provide mentorship to prospective animal scientists,” he adds. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept